About Enzene Biosciences
Enzene Biosciences is a company based in Pune (India) founded in 2006. Enzene Biosciences has raised $50 million across 1 funding round from investors including Eight Roads Ventures and F-Prime Capital. The company has 665 employees as of September 25, 2025. Enzene Biosciences offers products and services including EnzeneX Platform, Drug Discovery Services, Drug Development Services, and Drug Manufacturing Services. Enzene Biosciences operates in a competitive market with competitors including Hybio Pharmaceutical, AmbioPharm, Ocelot Bio, Rameda and Shaanxi Micot Technology, among others.
- Headquarter Pune, India
- Employees 665 as on 25 Sep, 2025
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Enzene Biosciences Limited
- Date of Incorporation 28 Aug, 2006
- Jurisdiction Pune, Maharashtra, India
-
Annual Revenue
$33.33 M (USD)88.93as on Mar 31, 2024
-
Net Profit
-$1.54 M (USD)24.22as on Mar 31, 2024
-
EBITDA
-$1.21 M (USD)70.24as on Mar 31, 2024
-
Total Equity Funding
$50 M (USD)
in 1 rounds
-
Latest Funding Round
$50 M (USD), Series C
Jan 30, 2023
-
Investors
Eight Roads Ventures
& 1 more
-
Employee Count
665
as on Sep 25, 2025
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Enzene Biosciences
Enzene Biosciences offers a comprehensive portfolio of products and services, including EnzeneX Platform, Drug Discovery Services, Drug Development Services, and Drug Manufacturing Services.
Continuous bioprocess for efficient biologics production and cost reduction
Solutions for target identification and antibody engineering processes
Support for cell line engineering and formulation development
Tech transfer and scale-up for biologics manufacturing
People of Enzene Biosciences
Unlock access to complete
Unlock access to complete
Funding Insights of Enzene Biosciences
Enzene Biosciences has successfully raised a total of $50M through 1 strategic funding round. The most recent funding activity was a Series C round of $50 million completed in January 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Enzene Biosciences
Enzene Biosciences has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Eight Roads Ventures and F-Prime Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investment and global platform support for startups.
|
Locked | Locked | Locked | |
|
Investments in life sciences, technology, healthtech, and crypto sectors from global locations.
|
Locked | Locked | Locked |
Investor details for Enzene Biosciences
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Enzene Biosciences
Investment portfolio details for Enzene Biosciences
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Enzene Biosciences
Detailed financials for Enzene Biosciences
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Enzene Biosciences Comparisons
Peer comparison for Enzene Biosciences
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Enzene Biosciences
Enzene Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Hybio Pharmaceutical, AmbioPharm, Ocelot Bio, Rameda and Shaanxi Micot Technology, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Polypeptide drugs and APIs are developed and manufactured.
|
|
| Locked | Locked | Locked |
CDMO and analytical services for peptide development are provided.
|
|
| Locked | Locked | Locked |
Ocelot Bio is a CDMO specializing in peptide manufacturing services.
|
|
| Locked | Locked | Locked |
Developer and manufacturer of generic pharmaceuticals, nutraceuticals, food supplements and veterinary products
|
|
| Locked | Locked | Locked |
Drug R&D services for cardiovascular and metabolic diseases are provided.
|
Detailed competitors of Enzene Biosciences
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Enzene Biosciences
Complete news archive for Enzene Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Enzene Biosciences
Enzene Biosciences was founded in 2006 and raised its 1st funding round 17 years after it was founded.
Enzene Biosciences is headquartered in Pune, India. It is registered at Pune, Maharashtra, India.
Enzene Biosciences is a funded company, having raised a total of $50M across 1 funding round to date.
As of Sep 25, 2025, the latest employee count at Enzene Biosciences is 665.
Annual revenue of Enzene Biosciences is $33.33M as on Mar 31, 2024.
Enzene Biosciences was founded in 2006 in Pune, India, as a subsidiary of Alkem Laboratories Limited. Operations are centered on biosimilars in the biotechnology sector, with platforms established in molecular biology, protein expression, and fermentation for microbial, insect, and mammalian cells. Expertise includes upstream and downstream process development, bio-analytics for peptides and proteins, cell-based bioassays, and peptide synthesis via solution and solid-state methods.
Enzene Biosciences's top competitors include Hybio Pharmaceutical, PolyPeptide and AmbioPharm.
Enzene Biosciences offers EnzeneX Platform, Drug Discovery Services, Drug Development Services, and Drug Manufacturing Services.
Enzene Biosciences has 2 investors. Key investors include Eight Roads Ventures, and F-Prime Capital.